SUBSCRIBE
SUBSCRIBE

bluebird bio

NEWS
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
bluebird bio’s Rare Blood Disorder Drug Tagged a Breakthrough by the FDA
February 2, 2015
 · 
2 min read
J.P. Morgan: Bluebird Bio Trading Near Historic Highs
Drug Development
J.P. Morgan: bluebird bio Soars On CEO’s Sickle Cell Data
January 15, 2015
 · 
2 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
BioCapital
bluebird bio’s New Blood Treatment Could Benefit Sickle Cell, Says Analyst
December 9, 2014
 · 
2 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
Biotech Bay
LentiGlobin Looks Promising On Sickle Cell For bluebird bio, Says Analyst
November 19, 2014
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots
September 18, 2025
 · 
4 min read
bluebird bio Strengthens Leadership Team With New Appointments
July 2, 2025
 · 
3 min read
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
June 2, 2025
 · 
6 min read
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
May 30, 2025
 · 
7 min read
bluebird bio Reminds Stockholders to Act Now to Tender Shares for Acquisition by Carlyle and SK Capital
May 27, 2025
 · 
5 min read
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
May 16, 2025
 · 
10 min read
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
May 14, 2025
 · 
6 min read
Important Information for bluebird bio Stockholders to Tender Shares for Acquisition by Carlyle and SK Capital
May 9, 2025
 · 
8 min read
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
May 6, 2025
 · 
11 min read
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
April 16, 2025
 · 
10 min read